Fig. 5
From: LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling
LINC02159 regulates YAP1 signaling in NSCLC through ALYREF-mediated m5C modification. A Hierarchical clustering showing differentially expressed mRNAs in control and LINC02159-knockdown groups. B Differential expression of mRNAs was displayed by the volcano map. C KEGG pathway enrichment analysis of down-regulated genes in RNA sequencing data. D The expression of tumor-related genes after LINC02159 knockdown according to RNA sequencing data. E YAP1 expression in NSCLC cells with LINC02159 knockdown. F YAP1 expression in NSCLC cells with ALYREF knockdown. G-I Western blot for YAP1 protein expression after knockdown (G) or overexpression (H) of LINC02159 and ALYREF knockdown (I). J, K The expression of Hippo pathway target genes after LINC02159 (J) and ALYREF knockdown (K). L RIP experiment for the interaction between ALYREF and 3’-UTR of YAP1. M RIP assays for the binding level of ALYREF to 3’-UTR of YAP1 after LINC02159 knockdown. N RIP assays for m5C level of the 3’-UTR of YAP1 in LINC02159-knockdown NSCLC cells. O The stability of YAP1 mRNA was measured in NSCLC cells with LINC02159 and ALYREF knockdown at the indicated time after Act D treatment (2 µg/mL). (*P < 0.05, **P < 0.01, ***P < 0.001, ns: no significance)